One study showed that low SMARCB1 expression promoted Bladder cancer growth by activating STAT3; therefore, targeting the IL6/JAK/STAT3 pathway is a potential treatment for SMARCB1-deficient tumors (28). Here, STAT3 is linked to urinary bladder cancer.